Overview of current modalities of colorectal cancer screening

Česká verzia

Authors: Ivana Mikoviny Kajzrlíková ¹; Petr Vítek ^1,2
Authors place of work: Beskydské Gastrocentrum, Interní oddělení Nemocnice ve Frýdku-Místku, p. o. ¹; Katedra interních oborů LF OU, Ostrava ²
Published in the journal: Vnitř Lék 2016; 62(4): 308-311
Category: Reviews

Summary

There are one-step and two-steps programs for colorectal cancer screening. The aim of all screening examinations is to detect early stage of the disease in asymptomatic patient. The aim of this article is actual review of current screening modalities such as fecal occult blood test, flexible sigmoideoscopy, colonoscopy, CT colonography, capsule endoscopy, blood-based tests and stool DNA tests. Colonoscopy still remains the gold standard for detection of colorectal neoplasias. In majority of countries worldwide programs for colorectal cancer screening are based on immunochemical fecal occult blood test followed by colonoscopy when positive.

Key words:
asymptomatic disease – colonoscopy – colorectal neoplasms – mass screening

Zdroje

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5): 759–767.

2. Manser CN, Bachmann LM, Brunner J et al. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc 2012; 76(1): 110–117.

3. Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366(8): 687–696.

4. Deyhle P. Colonic cancer – diagnosis, check-up, prevention. Internist (Berl) 1979; 20(1): 39–43.

5. Zavoral M, Suchanek S, Majek O et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014; 20(14): 3825–3834.

6. Jaffe RM, Kasten B, Young DS et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83(6): 824–826.

7. Fialová L. Hemoglobin ve stolici – okultní krvácení. In: Fialová L. Návody k praktickým cvičením z lékařské biochemie s klinicko-biochemickými aplikacemi. Medprint: Praha 2000.

8. Allison JE, Tekawa IS, Ransom LJ et al. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334(3): 155–159.

9. Allison JE, Sakoda LC, Levin TR et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99(19): 1462–1470.

10. Levin B, Lieberman DA, McFarland B et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58(3): 130–160.

11. Nakama H, Zhang B, Zhang X. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37(3): 398–401.

12. Kovarova JT, Zavoral M, Zima T et al. Improvements in colorectal cancer screening programmes – quantitative immunochemical faecal occult blood testing – how to set the cut-off for a particular population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156(2): 143–150.

13. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013; 49(14): 3049–3054.

14. Kovářová J. Kvantitativní test ve screeningu kolorektálního karcinomu – pohled do blízké budoucnosti. Gastroent Hepatol 2011; 65(2): 90–93.

15. Grazzini G, Ventura L, Zappa M et al. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district. Gut 2010; 59(11): 1511–1515.

16. Atkin WS, Edwards R, Kralj-Hans I et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375(9726): 1624–1633.

17. Schoenfeld P, Lipscomb S, Crook J et al. Accuracy of polyp detection by gastroenterologists and nurse endoscopists during flexible sigmoidoscopy: a randomized trial. Gastroenterology 1999; 117(2): 312–318.

18. Cooper MA, Tinmouth JM, Rabeneck L. Registered nurse-performed flexible sigmoidoscopy in Ontario: development and implementation of the curriculum and program. Can J Gastroenterol Hepatol 2014; 28(1): 13–18.

19. Hol L, van Leerdam ME, van Ballegooijen M et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59(1): 62–68.

20. Guittet L, Bouvier V, Mariotte N et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007; 56(2): 210–214.

21. Brenner H, Hoffmeister M, Arndt V et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102(2): 89–95.

22. Baxter NN, Goldwasser MA, Paszat LF et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009; 150(1): 1–8.

23. Singh H, Nugent Z, Demers AA et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010; 139(4): 1128–1137.

24. Lieberman D. A call to action – measuring the quality of colonoscopy. N Engl J Med 2006; 355(24): 2588–2589.

25. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362(19): 1795–1803.

26. Regula J, Rupinski M, Kraszewska E et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006; 355(18): 1863–1872.

27. Kaminski MF, Bretthauer M, Zauber AG et al. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012; 44(7): 695–702.

28. Burling D, Halligan S, Slater A et al. Potentially serious adverse events at CT colonography in symptomatic patients: national survey of the United Kingdom. Radiology 2006; 239(2): 464–471.

29. Johnson CD, Chen MH, Toledano AY et al. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008; 359(12): 1207–1217.

30. Rajapaksa RC, Macari M, Bini EJ. Prevalence and impact of extracolonic findings in patients undergoing CT colonography. J Clin Gastroenterol 2004; 38(9): 767–771.

31. Spada C, Hassan C, Sturniolo GC et al. Literature review and recommendations for clinical application of Colon Capsule Endoscopy. Dig Liver Dis 2011; 43(4): 251–258.

32. Holleran G, Leen R, O’Morain C et al. Colon capsule endoscopy as possible filter test for colonoscopy selection in a screening population with positive fecal immunology. Endoscopy 2014; 46(6): 473–478.

33. Zavoral M, Májek O, Tachecí I et al. Porovnání účinnosti kolonické kapslové endoskopie a kolonoskopie v detekci polypů a karcinomů tlustého střeva a konečníku – multicentrická, prospektivní, cross-over studie. Gastroent Hepatol 2014; 68(3): 218–224.

34. Pasricha T, Smith BF, Mitchell VR et al. Controlled colonic insufflation by a remotely triggered capsule for improved mucosal visualization. Endoscopy 2014; 46(7): 614–618.

35. Church TR, Wandell M, Lofton-Day C et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014; 63(2): 317–325.

36. Ladabaum U, Alvarez-Osorio L, Rösch T et al. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. Endoscopy International Open 2014; 2(2): E96-E104. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0034–1377182>.

37. Nollau P, Moser C, Weinland G et al. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996; 66(3): 332–336.

38. Deuter R, Müller O. Detection of APC mutations in stool DNA of patients with colorectal cancer by HD-PCR. Hum Mutat 1998; 11(1): 84–89.

39. Eguchi S, Kohara N, Komuta K et al. Mutations of the p53 gene in the stool of patients with resectable colorectal cancer. Cancer 1996; 77(8 Suppl): S1707-S1710.

40. Dong SM, Traverso G, Johnson C et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93(11): 858–865.

41. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. (Colorectal Cancer Study Group). Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351(26): 2704–2714.